FDA extends review period of GSK blood cancer drug momelotinib

GSK said on Friday that the US Food and Drug Administration has extended the review period of its new drug application for momelotinib, which is used to treat a blood cancer called myelofibrosis.

The review period has been extended by three months to provide time to review recently submitted data.

"GSK is confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review," it said.

Momelotinib is not currently approved in any market.